LongBio Pharma is a biotech company located in Shanghai, China. The company, which was founded in 2018, is focused on autoimmune and rare diseases, serving patients and society.
LongBio Pharma aims to bring our drugs to both domestic and international markets with our partners, especially to bring patients with more affordable and high-quality bio-medicines.
SunDomaTM is a super high affinity antibody R&D technology platform developed by Longbio. The technology is developed based on the more than 30 years of experience in hybridoma technology by its co-founder Dr. Sun, Bill Nai-chau. Based on this platform, Longbio has developed a new generation of IgE antibody LP-003.
InCibitorTM is a new generation of complement inhibitor platform independently developed by Longbio. The bi-functional complement inhibitor LP-005 developed based on this platform is now on Phase II stage. Longbio is also exploring the development of drugs related to hematology, nephrology, neurology, ophthalmology, oncology, and gene therapy based on this platform.
NeXineTM is the next-generation long-acting cytokine technology platform independently developed by Longbio. The platform is based on the co-founder, Dr. Sun's fc-fusion protein technology, and multiple candidate cytokine drug molecules have been developed based on this platform.
SunDomaTM is a super high affinity antibody R&D technology platform developed by Longbio. The technology is developed based on the more than 30 years of experience in hybridoma technology by its co-founder Dr. Sun, Bill Nai-chau. Based on this platform, Longbio has developed a new generation of IgE antibody LP-003.
InCibitorTM is a new generation of complement inhibitor platform independently developed by Longbio. The bi-functional complement inhibitor LP-005 developed based on this platform is now on Phase II stage. Longbio is also exploring the development of drugs related to hematology, nephrology, neurology, ophthalmology, oncology, and gene therapy based on this platform.
NeXineTM is the next-generation long-acting cytokine technology platform independently developed by Longbio. The platform is based on the co-founder, Dr. Sun's fc-fusion protein technology, and multiple candidate cytokine drug molecules have been developed based on this platform.
longBio
News